Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
Source: View publication →
In adults with type 2 diabetes and high cardiovascular and renal risk, the addition of linagliptin to standard care was noninferior to placebo for major adverse cardiovascular events and did not increase the risk of hospitalization for heart failure.
Key Findings
Study Design
Study Limitations
Clinical Significance
CARMELINA firmly established the cardiovascular and renal safety of linagliptin in a high-risk population of patients with type 2 diabetes, notably including a large proportion with advanced chronic kidney disease. Crucially, it demonstrated no increased risk for heart failure hospitalization, alleviating a class-wide concern raised by earlier DPP-4 inhibitor trials, and confirmed that linagliptin can be safely used without dose adjustment across a broad spectrum of renal impairment.
Historical Context
Following the 2008 FDA mandate requiring cardiovascular outcome trials (CVOTs) for all new type 2 diabetes medications, several dipeptidyl peptidase-4 (DPP-4) inhibitors underwent rigorous safety evaluation. While earlier trials like SAVOR-TIMI 53 (saxagliptin) and EXAMINE (alogliptin) confirmed overall macrovascular safety, they raised unexpected concerns about an increased risk of heart failure hospitalization. CARMELINA was designed to comprehensively evaluate linagliptin, with a unique focus on a population carrying a substantial burden of chronic kidney disease—a demographic often excluded from prior CVOTs despite being highly prevalent in clinical practice. The subsequent CAROLINA trial further bolstered linagliptin's safety profile by demonstrating noninferiority against an active sulfonylurea comparator (glimepiride).
Guided Discussion
High-yield insights from every perspective
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. How does inhibiting the DPP-4 enzyme improve glycemic control in type 2 diabetes, and why does it have a lower risk of hypoglycemia compared to sulfonylureas?
Key Response
DPP-4 degrades incretin hormones like GLP-1 and GIP. Inhibiting it prolongs their action, which stimulates insulin release and inhibits glucagon secretion in a glucose-dependent manner, minimizing hypoglycemia risk compared to insulin secretagogues.
Given the CARMELINA findings that linagliptin is safe but lacks cardiovascular or renal benefit, how does this trial influence your decision to prescribe a DPP-4 inhibitor versus an SGLT2 inhibitor or GLP-1 receptor agonist in a patient with T2DM and stage 3 CKD?
Key Response
SGLT2is and GLP-1 RAs have proven CV and renal benefits and are preferred first-line add-ons. Linagliptin is reserved for patients who cannot tolerate these agents or need additional glycemic control without weight gain or hypoglycemia, as CARMELINA proves its safety but not superiority.
The SAVOR-TIMI 53 trial showed an increased risk of hospitalization for heart failure with saxagliptin. How does the CARMELINA trial address the concern of a class effect regarding heart failure risk among DPP-4 inhibitors, particularly in a high-risk renal population?
Key Response
CARMELINA demonstrated no increased risk of heart failure hospitalization with linagliptin, even in a population highly susceptible to HF (advanced CKD). This, along with TECOS (sitagliptin), suggests that the HF risk seen with saxagliptin is likely not a uniform class effect.
Among the DPP-4 inhibitors, linagliptin has unique pharmacokinetics. Why was linagliptin specifically an ideal candidate to study in the CARMELINA population, which included patients with advanced chronic kidney disease, and how does this affect practical prescribing?
Key Response
Unlike other DPP-4 inhibitors that are primarily renally excreted and require dose adjustments in CKD, linagliptin is primarily excreted via the biliary and fecal route. Thus, it requires no dose adjustment regardless of the degree of renal impairment, simplifying prescribing.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The CARMELINA trial used a non-inferiority design for its primary MACE outcome. What are the methodological challenges in defining the non-inferiority margin for a trial evaluating a diabetes drug's cardiovascular safety, and how does the upper bound of the confidence interval impact interpretation?
Key Response
Historically, FDA guidance required the upper bound of the 95% CI for the hazard ratio of MACE to be less than 1.3 to rule out unacceptable CV risk. Choosing this margin balances clinical safety with achievable sample sizes, though excluding 1.3 only establishes safety, not superiority.
In evaluating CVOTs like CARMELINA, use of off-protocol cardioprotective or glycemic medications can occur. How should a peer reviewer assess the impact of such post-randomization drop-in confounding on the trial's non-inferiority and superiority conclusions?
Key Response
If patients in the placebo group start active, proven therapies (like SGLT2is), the placebo group's event rate may fall, making it easier to show non-inferiority but harder to show superiority. Reviewers must scrutinize the balance of rescue medications to ensure results are not biased toward the null.
ADA and KDIGO guidelines strongly recommend SGLT2 inhibitors and GLP-1 RAs for patients with T2DM and CKD or high CV risk. Based on CARMELINA's findings, what specific role should linagliptin be assigned in the treatment algorithm for patients with diabetic kidney disease?
Key Response
Linagliptin should be positioned as a safe, second- or third-line agent for glycemic control in patients with T2DM and CKD who have contraindications to SGLT2is and GLP-1 RAs, or who require additional A1c lowering, as it offers established cardiovascular and renal safety but lacks disease-modifying benefits.
Clinical Landscape
Noteworthy Related Trials
SAVOR-TIMI 53
Tested
Saxagliptin 5 mg daily
Population
T2DM patients with a history of or high risk for cardiovascular events
Comparator
Placebo
Endpoint
3-point MACE
EXAMINE
Tested
Alogliptin 25 mg daily
Population
T2DM patients with recent acute coronary syndrome
Comparator
Placebo
Endpoint
3-point MACE
TECOS
Tested
Sitagliptin 100 mg daily
Population
T2DM patients with established cardiovascular disease
Comparator
Placebo
Endpoint
4-point MACE
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis